**Core tip:** Asian American patients with non-metastatic gastric cancer have better overall and disease-free survival compared to other racial groups in the United States. These findings are thought-provoking for the potential biological mechanisms underlying this observation as well as the potential therapeutic implications of these findings.

INTRODUCTION
============

Gastric cancer is one of the most common causes of mortality and morbidity ascribed to cancer diagnosis worldwide\[[@B1]\]. A considerable geographical variation exists with regards to its etiology as well as its incidence\[[@B2]\]. Compared to Western countries, many Asian countries have a higher incidence of gastric cancer\[[@B3]\].

It has been recognized for a long time that gastric cancer behavior and outcomes might be different between patients living in Asian countries *vs* patients living in Western countries\[[@B4]\]. Possible reasons for these differences might be related to differences in etiology, biology, stage at presentation, or therapeutic approaches between the two categories of patients\[[@B5]\]. However, it is not yet fully clear if these differences persist between patients of Asian ancestry and patients of other racial subgroups within the multiethnic communities of North America.

A few previously published retrospective studies have suggested a difference between Asian American and other racial groups in the United States\[[@B6],[@B7]\]. These studies were, however, criticized because of the potential -unaccounted for- confounders that frequently accompany retrospective studies. This made their conclusions far from decisive.

To provide a better answer for this question, there is a need to approach this question within the context of a prospectively collected dataset that adequately reports on baseline demographic characteristics of included patients as well as treatments received. Project Data Sphere (PDS) provides an ideal opportunity to tackle this question within the context of a controlled clinical trial\[[@B8]\]. The CALGB 80101 trial (NCT00052910), which evaluated two adjuvant chemoradiotherapy schedules for resected gastric cancer, was downloaded from the PDS platform to tackle this research question.

Objective
---------

The current study aims at evaluating the impact of race on survival outcomes of non-metastatic gastric cancer patients in the United States treated with surgery plus adjuvant treatment.

MATERIALS AND METHODS
=====================

About the CALGB 80101 Study
---------------------------

This is a randomized phase III study evaluating two different adjuvant chemoradiotherapy schedules following resection of non-metastatic gastric cancer. These two schedules are: (1) 5-fluorouracil/leucovorin for 5 d on cycles 1,3,4 and 5-fluorouracil continuous intravenous infusion for 5 wk in cycle 2 concurrent with radiation therapy; and (2) Epirubicin/cisplatin/5-fluorouracil for cycles 1,3,4 and 5-fluorouracil continuous intravenous infusion for 5 wk in cycle 2 concurrent with radiation therapy. The start date of the study was in December 2002, and the primary completion date was in June 2012. Patients were included in this study regardless of the extent of nodal dissection. Detailed eligibility, methods, and primary results of this study were published elsewhere. The records of a total of 546 patients were available from the included study\[[@B9]\].

Data collection
---------------

The following information was collected (where available) from each of the included participants in the current study: Age at diagnosis, sex, race, ethnicity, performance status, history of prior cancer, T stage, N stage, lymph node ratio (defined as the ratio between positive and examined lymph nodes), histologic grade, primary tumor site, assigned treatment arm, and reason of stoppage of treatment. Type of lymph node dissection (D1 *vs* D2) was not available in the downloaded study datasets.

Primary endpoints for the current study include overall survival (defined as the time from randomization till death of any reason) and disease-free survival (defined as the time from randomization till death or progressive disease diagnosis).

Statistical analyses
--------------------

Descriptive statistics were initially utilized to explore frequencies and distribution of different baseline parameters in the studied cohort. Chi-Squared testing was then used to explore the distribution of baseline characteristics between Asian Americans and other racial subgroups in the United States.

Kaplan-Meier analysis and log-rank testing were utilized to explore the overall and disease-free survival differences according to the race of the patients. Univariate and multivariate Cox regression analyses were then used to explore factors affecting overall and disease-free survivals. Factors with *P* \< 0.05 in univariate analysis were subsequently included into multivariate analysis. SPSS statistics (version 20; IBM; Armonk, NY, United States) was used to execute all statistical procedures. *P* \< 0.05 was used as an indicator of statistical significance.

RESULTS
=======

Characteristics of included patients
------------------------------------

Among the included patients, 46.2% were ≥ 60-years-old, 67.9% were males, 73.8% have white race (*vs* 12.8% black Americans and 8.2% Asian Americans), and only a minority of patients were of Hispanic ethnicity (9.9%). Almost half of the patients had an Eastern Cooperative Oncology Group performance score of 0, only 4% of patients had a history of another cancer, and most patients had node-positive disease. The study cohort was almost equally divided between the two treatment arms, and most patients (65.8%) completed the planned course of treatment (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics of patients included in the current analysis, 546 patients

  **Parameter**                                                   ***n* (%)**
  --------------------------------------------------------------- -------------
  Age                                                             
  \< 60 yr                                                        294 (53.8)
  ≥ 60 yr                                                         252 (46.2)
  Sex                                                             
  Male                                                            371 (67.9)
  Female                                                          175 (32.1)
  Race                                                            
  White                                                           403 (73.8)
  Black                                                           70 (12.8)
  Asian                                                           45 (8.2)
  Others                                                          28 (5.1)
  Ethnicity                                                       
  Hispanic                                                        54 (9.9)
  Non-Hispanic                                                    445 (81.5)
  Unknown                                                         47 (8.6)
  Performance status                                              
  0                                                               276 (50.5)
  1                                                               257 (47.1)
  2                                                               13 (2.4)
  History of prior cancer                                         
  Yes                                                             22 (4)
  No                                                              516 (94.5)
  Unknown                                                         8 (1.5)
  T stage                                                         
  T1                                                              33 (6)
  T2                                                              219 (40.1)
  T3                                                              259 (47.4)
  T4                                                              23 (4.2)
  Unknown                                                         12 (2.2)
  N stage                                                         
  N0                                                              77 (14.1)
  N1                                                              312 (57.1)
  N2                                                              105 (19.2)
  N3                                                              34 (6.2)
  Unknown                                                         18 (3.3)
  Lymph node ratio (mean; SD)                                     0.32; 0.307
  Histologic grade                                                
  Grade 1                                                         15 (2.7)
  Grade 2                                                         139 (25.5)
  Grade 3                                                         360 (65.9)
  Grade 4                                                         17 (3.1)
  Unknown                                                         15 (2.8)
  Primary tumor site                                              
  GEJ/ cardia/ fundus                                             208 (38.1)
  Body/antrum/ pylorus                                            161 (29.5)
  Others, NOS                                                     177 (32.4)
  Treatment arm                                                   
  5FU/LCV + RT                                                    280 (51.3)
  ECF + RT                                                        266 (48.7)
  Completion Of treatment                                         
  Completed as planned                                            359 (65.8)
  Stopped because of adverse events                               64 (11.7)
  Stopped because of progression/death                            33 (6)
  Stopped because of other reasons (*e.g*., consent withdrawal)   90 (16.5)

RT: Radiation therapy; NOS: Not otherwise specified; SD: Standard deviation; GEJ: Gastroesophageal junction.

Comparing Asian Americans with other racial groups, Asian Americans were less likely to have an Eastern Cooperative Oncology Group score of 0 (48.9% *vs* 50.7%; *P* \< 0.001). On the other hand, there was no difference between Asian Americans and other racial groups with regards to sex (*P* = 0.233), age group (*P* = 0.810), history of prior cancer (*P* = 0.873), histologic grade (*P* = 0.067), T stage (*P* = 0.614), N stage (*P* = 0.867), or assigned treatment arm (*P* = 0.737) (Table [2](#T2){ref-type="table"}).

###### 

Comparison of baseline demographic/treatment characteristics between Asian Americans and other racial groups, *n* (%)

  **Variable**              **Asian Americans, 45 patients**   **Other patients, 501 patients**   ***P* value**
  ------------------------- ---------------------------------- ---------------------------------- ---------------
  Age                                                                                             0.810
  \< 60 yr                  25 (55.6)                          269 (53.7)                         
  ≥ 60 yr                   20 (44.4)                          232 (46.3)                         
  ECOG Performance score                                                                          \< 0.001
  0                         22 (48.9)                          254 (50.7)                         
  1                         18 (40)                            239 (47.7)                         
  2                         5 (11.1)                           8 (1.6)                            
  Sex                                                                                             0.233
  Male                      27 (60)                            344 (68.7)                         
  Female                    18 (40)                            157 (31.3)                         
  History of prior cancer                                                                         0.873
  Yes                       2 (4.5)                            20 (4)                             
  No                        42 (95)                            474 (95.5)                         
  Unknown                   1(0.5)                             7 (0.5)                            
  T stage                                                                                         0.614
  T1-2                      20 (44.4)                          232 (46.3)                         
  T3-4                      24 (53.4)                          258 (51.5)                         
  Unknown                   1 (2.2)                            11 (2.2)                           
  N stage                                                                                         0.867
  N 0                       8 (17.8)                           69 (13.8)                          
  N 1-3                     35 (77.8)                          416 (83)                           
  Unknown                   2 (4.4)                            16 (3.2)                           
  Histologic grade                                                                                0.067
  Grade 1-2                 6 (11.7)                           148 (29)                           
  Grade 3-4                 38 (86.3)                          339 (68)                           
  Unknown                   1 (2)                              14 (3)                             
  Treatment arm                                                                                   0.737
  5FU/LCV + RT              22 (48.9)                          258 (51.5)                         
  ECF + RT                  23 (51.1)                          243 (48.5)                         

ECOG: Eastern Cooperative Oncology Group; 5FU: 5-Fluorouracil; LCV: Leucovorin; RT: Radiotherapy; ECF: Epirubicin, cisplatin, 5-fluoruracil.

Survival outcomes according to racial groups
--------------------------------------------

Using Kaplan-Meier analysis/log-rank testing, Asian Americans appear to have better overall and disease-free survival outcomes compared to other United States racial groups (White Americans, Black Americans, and other racial groups) (*P* = 0.011; *P* = 0.010; respectively) (Figure [1](#F1){ref-type="fig"}).

![Kaplan-Meier analysis. A: Kaplan-Meier analysis of the impact of race on overall survival; B: Kaplan-Meier analysis of the impact of race on disease-free survival.](WJGO-11-1151-g001){#F1}

Univariate analysis was then utilized to explore factors affecting overall and disease-free survival in the studied cohort. The following factors were evaluated in the univariate analysis: Age at diagnosis, race, performance status, sex, ethnicity, history of prior cancer, T stage, lymph node ratio, histologic grade, tumor site, and treatment arm. For both endpoints, the following factors were significant in univariate analysis (*P* \< 0.05): T stage, lymph node ratio, primary tumor site, and race. When including these factors in a multivariate analysis for overall survival, the following factors were predictive of better overall survival: Asian American race (hazard ratio (HR) *vs* white race: 0.438; 95% confidence interval (CI): 0.254-0.754 , *P* = 0.003), lower T stage (HR for T4 *vs* T1: 3.807; 95%CI:1.731-8.361; *P* = 0.001), lower lymph node ratio (HR with increasing lymph node ratio: 3.004; 95%CI: 2.154-4.190; *P* \< 0.001), and distal site of tumor primary (HR for proximal *vs* distal tumor: 1.523; 95%CI: 1.138-2.037; *P* = 0.005). Likewise, when including these factors in a multivariate analysis for disease-free survival, the following factors were predictive of better disease-free survival: Asian American race (HR *vs* white race: 0.460: 95%CI: 0.280-0.755, *P* = 0.002), lower T stage (HR for T4 *vs* T1: 3.990; 95%CI: 1.885-8.443; *P* \< 0.001), lower lymph node ratio (HR with increasing lymph node ratio: 2.471; 95%CI: 1.801-3.390; *P* \< 0.001), and distal site of tumor primary (HR for proximal *vs* distal tumor: 1.367; 95%CI: 1.042-1.793; *P* = 0.024) (Table [3](#T3){ref-type="table"}).

###### 

Multivariate Cox-regression analysis for factors affecting overall and disease-specific survival

  **Parameter**                  **Overall survival**   **Disease-specific survival**                         
  ------------------------------ ---------------------- ------------------------------- --------------------- ----------
  Race                                                                                                        
  White                          Reference                                              Reference             
  Black                          1.020 (0.717-1.453)    0.911                           0.962 (0.684-1.353)   0.825
  Asian                          0.438 (0.254-0.754)    0.003                           0.460 (0.280-0.755)   0.002
  Lymph node ratio, continuous   3.004 (2.154-4.190)    \< 0.001                        2.471 (1.801-3.390)   \< 0.001
  T stage                                                                                                     
  T1                             Reference                                              Reference             
  T2                             1.680 (0.878- 3.215)   0.117                           1.895 (1.020-3.520)   0.043
  T3                             2.517 (1.321-4.798)    0.005                           3.042 (1.643-5.632)   \< 0.001
  T4                             3.807 (1.731-8.361)    0.001                           3.990 (1.885-8.443)   \< 0.001
  Primary site                                                                                                
  Body/antrum/pylorus            Reference                                              Reference             
  GEJ/cardia/fundus              1.523 (1.138-2.037)    0.005                           1.367 (1.042-1.793)   0.024

GEJ: Gastroesophageal junction; CI: Confidence interval.

DISCUSSION
==========

The current study evaluated the impact of racial affiliation on the outcomes of non-metastatic United States gastric cancer patients. It suggests that Asian Americans with non-metastatic gastric cancer have better overall and disease-free survival compared to other racial groups in the United States.

These findings are consistent with previously reported population-based studies that suggested that United States gastric cancer patients of Asian Ancestry have better survival outcomes compared to other racial groups\[[@B10],[@B11]\]. However, the current study is unique in being based on a controlled dataset that was collected in the context of a well-conducted randomized study.

Previous multinational comparisons have also suggested that Asian gastric cancer patients have better survival outcomes compared to other gastric cancer patients from other ethnic backgrounds\[[@B12],[@B13]\]. It was previously postulated that this might be the result of an earlier stage at diagnosis and/or more aggressive surgical approach (particularly with regards to D2 dissection approach)\[[@B14]\]. However, the current study suggests that such differences cannot be explained by these factors alone. Asian American patients were treated in North America (according to the same surgical standard of other racial groups), and the current study does not show clear evidence of a uniquely earlier stage at diagnosis. It is not known, however, if patients labeled in the current study as Asian Americans were of first or subsequent generation of Asian Americans. Thus, one cannot exclude completely the potential contribution of environmental/ social differences between the East and the West. Additional factors that might explain these findings are potential biological differences between Asian and Caucasian patients with gastric cancer. Previous studies suggested that the predominant biological/ topographical subtype of gastric cancer among Asian patients might be different from the one that is prevalent among Caucasian patients\[[@B15]\]. Likewise, the variable role of *Helicobacter Pylori* infection as a carcinogenic factor between different ethnic groups might also be a factor here\[[@B16]\]. Further studies are needed to confirm or refute this hypothesis.

The current study has several limitations that need to be appreciated: Foremost, although the current study is based on a randomized prospective study, the specific question of the impact of race on outcomes was not a priori question within this study but rather an exploratory subsequent question. Thus, the current study is still a retrospective study of a prospectively collected dataset. Second, the current study contains a relatively small number of patients; confirmation of these findings in a larger prospective cohort is needed. These weaknesses need to be weighed against the clear strengths of the current study; most notably, the reliance on controlled well-conducted clinical trial dataset that provides a far more credible comparison compared to traditional retrospective, population-based studies.

The current study might also be informative for future research efforts of gastric cancer both in North America as well as in other parts of the world. Future randomized studies involving gastric cancer patients in North America should include a priori subgroup analysis for Asian Americans *vs* other racial groups. Moreover, additional exploration of the outcomes of first-generation *vs* second and subsequent generation Asian Americans are needed to dissect possible environmental/ social factors from potential biological differences. Likewise, a comparison of the outcomes of Asian Americans *vs* Asians living in Asian countries within a multinational context would also be useful for the same purpose. Moreover, national and international consortia working on the genetic mapping of gastric cancer should also pay additional attention to the possible differences in gastric cancer behavior (and possibly biology) among different ethnic groups.

The current study also further confirms the current practice of requiring confirmation of clinical trial results conducted exclusively on Asian patients (*e.g*., Japanese trials) prior to generalization to western patients (and vice versa). The clear differences in outcomes of Asian *vs* Caucasian patients (treated within the same clinical trial/ health care system) mandate greater caution prior to the generalization of clinical trial results.

It should also be noted that the term "Asian Americans" includes quite a broad category of ethnicities, and the outcomes of gastric cancer might be variable among these ethnicities as well. Unfortunately, the current study dataset does not differentiate between different Asian American ethnic subgroups. This is another area of research that needs to be tackled in the future.

In conclusion, the current study suggests that Asian American patients with non-metastatic gastric cancer have better overall and disease-free survival compared to other racial groups in the United States. Further preclinical and clinical research is needed to clarify the reasons behind this observation.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Gastric cancer behavior and outcomes might be different between patients living in Asian countries *vs* patients living in Western countries. It is not clear if these differences would persist between patients of Asian ancestry and patients of other racial subgroups within the multiethnic communities of North America.

Research motivation
-------------------

This study hypothesizes that these differences will present within North American multiethnic communities.

Research objectives
-------------------

To evaluate the impact of race on survival outcomes of non-metastatic gastric cancer patients in the United States.

Research methods
----------------

This is a secondary analysis of a randomized controlled trial (CALGB 80101 study) that evaluated two adjuvant chemoradiotherapy schedules following resection of non-metastatic gastric cancer. Kaplan-Meier analysis and log-rank testing were utilized to explore the overall and disease-free survival differences according to the race of the patients. Univariate and multivariate Cox regression analyses were then used to explore factors affecting overall and disease-free survival.

Research results
----------------

A total of 546 patients were included in the current analysis. Of which, 73.8% have white race (*vs* 12.8% black Americans and 8.2% Asian Americans). Using Kaplan-Meier analysis/log-rank testing, Asian Americans appear to have better overall and disease-free survival outcomes compared to other United States racial groups (White Americans, Black Americans and other racial groups) (*P* = 0.011; *P* = 0.010; respectively). Moreover, in an adjusted multivariate model, Asian American race seems to be associated with better overall and disease-free survival (hazard ratio: 0.438; 95%CI: 0.254-0.754), *P* = 0.003; hazard ratio: 0.460; 95%CI: 0.280-0.755, *P* = 0.002; respectively).

Research conclusions
--------------------

Asian American patients with non-metastatic gastric cancer have better overall and disease-free survival compared to other racial groups in the United States. Further preclinical and clinical research is needed to clarify the reasons behind this observation.

Research perspectives
---------------------

The findings of this study are thought-provoking for the potential biological mechanisms underlying this observation as well as the potential therapeutic implications of these findings.
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